Cancer - Wiki-Pi

Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide
AKT2 and XIAP	v-akt murine thymoma viral oncogene homolog 2	X-linked inhibitor of apoptosis, E3 ubiquitin protein ligase	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Activation of BH3-only proteins mTOR signalling Signaling by Wnt Activation of PKB Signaling by EGFRvIII in Cancer AKT phosphorylates targets in the cytosol Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling Regulation of beta-cell development PI3K/AKT activation PI-3K cascade RNF mutants show enhanced WNT signaling and proliferation PDE3B signalling PKB-mediated events PI3K Cascade Signaling by PDGF Downregulation of ERBB2:ERBB3 signaling DAP12 interactions GAB1 signalosome misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling G-protein beta:gamma signalling CD28 co-stimulation CD28 dependent PI3K/Akt signaling PDE3B signalling Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by ERBB2 Activation of BAD and translocation to mitochondria Signaling by EGFR GPCR downstream signaling Signaling by VEGF AKT phosphorylates targets in the nucleus Downstream signal transduction Regulation of gene expression in beta cells Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Platelet activation, signaling and aggregation Adaptive Immune System Inhibition of TSC complex formation by PKB Activation of PKB Costimulation by the CD28 family IRS-mediated signalling PIP3 activates AKT signaling mTOR signalling Translocation of GLUT4 to the plasma membrane IGF1R signaling cascade deactivation of the beta-catenin transactivating complex VEGFA-VEGFR2 Pathway IRS-related events triggered by IGF1R G beta:gamma signalling through PI3Kgamma PI3K events in ERBB2 signaling VEGFR2 mediated vascular permeability Downstream signaling of activated FGFR Programmed Cell Death XAV939 inhibits tankyrase, stabilizing AXIN Intrinsic Pathway for Apoptosis Signaling by Insulin receptor Innate Immune System Signalling by NGF Insulin receptor signalling cascade CTLA4 inhibitory signaling AKT-mediated inactivation of FOXO1A Signaling by Ligand-Responsive EGFR Variants in Cancer IRS-related events NGF signalling via TRKA from the plasma membrane Negative regulation of the PI3K/AKT network Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of TSC complex formation by PKB Signaling by FGFR IRS-mediated signalling TCF dependent signaling in response to WNT Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) GPVI-mediated activation cascade Signaling by WNT in cancer PKB-mediated events PI3K Cascade	misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling SMAC binds to IAPs SMAC-mediated dissociation of IAP:caspase complexes SMAC-mediated apoptotic response Signaling by Wnt deactivation of the beta-catenin transactivating complex Apoptotic factor-mediated response TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation Programmed Cell Death XAV939 inhibits tankyrase, stabilizing AXIN Signaling by WNT in cancer Intrinsic Pathway for Apoptosis	N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	1-[3,3-Dimethyl-2-(2-Methylamino-Propionylamino)-Butyryl]-Pyrrolidine-2-Carboxylic Acid(1,2,3,4-Tetrahydro-Naphthalen-1-Yl)-Amide N-METHYLALANYL-3-METHYLVALYL-4-PHENOXY-N-(1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)PROLINAMIDE
AKT2 and TSC2	v-akt murine thymoma viral oncogene homolog 2	tuberous sclerosis 2	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Activation of BH3-only proteins mTOR signalling Signaling by Wnt Activation of PKB Signaling by EGFRvIII in Cancer AKT phosphorylates targets in the cytosol Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling Regulation of beta-cell development PI3K/AKT activation PI-3K cascade RNF mutants show enhanced WNT signaling and proliferation PDE3B signalling PKB-mediated events PI3K Cascade Signaling by PDGF Downregulation of ERBB2:ERBB3 signaling DAP12 interactions GAB1 signalosome misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling G-protein beta:gamma signalling CD28 co-stimulation CD28 dependent PI3K/Akt signaling PDE3B signalling Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by ERBB2 Activation of BAD and translocation to mitochondria Signaling by EGFR GPCR downstream signaling Signaling by VEGF AKT phosphorylates targets in the nucleus Downstream signal transduction Regulation of gene expression in beta cells Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Platelet activation, signaling and aggregation Adaptive Immune System Inhibition of TSC complex formation by PKB Activation of PKB Costimulation by the CD28 family IRS-mediated signalling PIP3 activates AKT signaling mTOR signalling Translocation of GLUT4 to the plasma membrane IGF1R signaling cascade deactivation of the beta-catenin transactivating complex VEGFA-VEGFR2 Pathway IRS-related events triggered by IGF1R G beta:gamma signalling through PI3Kgamma PI3K events in ERBB2 signaling VEGFR2 mediated vascular permeability Downstream signaling of activated FGFR Programmed Cell Death XAV939 inhibits tankyrase, stabilizing AXIN Intrinsic Pathway for Apoptosis Signaling by Insulin receptor Innate Immune System Signalling by NGF Insulin receptor signalling cascade CTLA4 inhibitory signaling AKT-mediated inactivation of FOXO1A Signaling by Ligand-Responsive EGFR Variants in Cancer IRS-related events NGF signalling via TRKA from the plasma membrane Negative regulation of the PI3K/AKT network Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of TSC complex formation by PKB Signaling by FGFR IRS-mediated signalling TCF dependent signaling in response to WNT Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) GPVI-mediated activation cascade Signaling by WNT in cancer PKB-mediated events PI3K Cascade	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Regulation of Rheb GTPase activity by AMPK mTOR signalling AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade PKB-mediated events PI3K Cascade Signaling by PDGF DAP12 interactions GAB1 signalosome Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Inhibition of TSC complex formation by PKB PIP3 activates AKT signaling IRS-mediated signalling mTOR signalling IGF1R signaling cascade IRS-related events triggered by IGF1R PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Energy dependent regulation of mTOR by LKB1-AMPK Signaling by Insulin receptor Innate Immune System Signalling by NGF Insulin receptor signalling cascade IRS-related events Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Inhibition of TSC complex formation by PKB Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by FGFR IRS-mediated signalling Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) PKB-mediated events PI3K Cascade	N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
AKT2 and APOB	v-akt murine thymoma viral oncogene homolog 2	apolipoprotein B	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Activation of BH3-only proteins mTOR signalling Signaling by Wnt Activation of PKB Signaling by EGFRvIII in Cancer AKT phosphorylates targets in the cytosol Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling Regulation of beta-cell development PI3K/AKT activation PI-3K cascade RNF mutants show enhanced WNT signaling and proliferation PDE3B signalling PKB-mediated events PI3K Cascade Signaling by PDGF Downregulation of ERBB2:ERBB3 signaling DAP12 interactions GAB1 signalosome misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling G-protein beta:gamma signalling CD28 co-stimulation CD28 dependent PI3K/Akt signaling PDE3B signalling Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by ERBB2 Activation of BAD and translocation to mitochondria Signaling by EGFR GPCR downstream signaling Signaling by VEGF AKT phosphorylates targets in the nucleus Downstream signal transduction Regulation of gene expression in beta cells Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Platelet activation, signaling and aggregation Adaptive Immune System Inhibition of TSC complex formation by PKB Activation of PKB Costimulation by the CD28 family IRS-mediated signalling PIP3 activates AKT signaling mTOR signalling Translocation of GLUT4 to the plasma membrane IGF1R signaling cascade deactivation of the beta-catenin transactivating complex VEGFA-VEGFR2 Pathway IRS-related events triggered by IGF1R G beta:gamma signalling through PI3Kgamma PI3K events in ERBB2 signaling VEGFR2 mediated vascular permeability Downstream signaling of activated FGFR Programmed Cell Death XAV939 inhibits tankyrase, stabilizing AXIN Intrinsic Pathway for Apoptosis Signaling by Insulin receptor Innate Immune System Signalling by NGF Insulin receptor signalling cascade CTLA4 inhibitory signaling AKT-mediated inactivation of FOXO1A Signaling by Ligand-Responsive EGFR Variants in Cancer IRS-related events NGF signalling via TRKA from the plasma membrane Negative regulation of the PI3K/AKT network Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of TSC complex formation by PKB Signaling by FGFR IRS-mediated signalling TCF dependent signaling in response to WNT Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) GPVI-mediated activation cascade Signaling by WNT in cancer PKB-mediated events PI3K Cascade	Lipoprotein metabolism LDL-mediated lipid transport Metabolism of lipids and lipoproteins Chylomicron-mediated lipid transport Lipid digestion, mobilization, and transport Diseases associated with visual transduction Cell surface interactions at the vascular wall Platelet homeostasis Visual phototransduction Scavenging by Class H Receptors Platelet sensitization by LDL Scavenging by Class F Receptors Scavenging by Class A Receptors Scavenging by Class B Receptors Orphan transporters Retinoid metabolism and transport	N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
AKT2 and AKT1S1	v-akt murine thymoma viral oncogene homolog 2	AKT1 substrate 1 (proline-rich)	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Activation of BH3-only proteins mTOR signalling Signaling by Wnt Activation of PKB Signaling by EGFRvIII in Cancer AKT phosphorylates targets in the cytosol Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling Regulation of beta-cell development PI3K/AKT activation PI-3K cascade RNF mutants show enhanced WNT signaling and proliferation PDE3B signalling PKB-mediated events PI3K Cascade Signaling by PDGF Downregulation of ERBB2:ERBB3 signaling DAP12 interactions GAB1 signalosome misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling G-protein beta:gamma signalling CD28 co-stimulation CD28 dependent PI3K/Akt signaling PDE3B signalling Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by ERBB2 Activation of BAD and translocation to mitochondria Signaling by EGFR GPCR downstream signaling Signaling by VEGF AKT phosphorylates targets in the nucleus Downstream signal transduction Regulation of gene expression in beta cells Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Platelet activation, signaling and aggregation Adaptive Immune System Inhibition of TSC complex formation by PKB Activation of PKB Costimulation by the CD28 family IRS-mediated signalling PIP3 activates AKT signaling mTOR signalling Translocation of GLUT4 to the plasma membrane IGF1R signaling cascade deactivation of the beta-catenin transactivating complex VEGFA-VEGFR2 Pathway IRS-related events triggered by IGF1R G beta:gamma signalling through PI3Kgamma PI3K events in ERBB2 signaling VEGFR2 mediated vascular permeability Downstream signaling of activated FGFR Programmed Cell Death XAV939 inhibits tankyrase, stabilizing AXIN Intrinsic Pathway for Apoptosis Signaling by Insulin receptor Innate Immune System Signalling by NGF Insulin receptor signalling cascade CTLA4 inhibitory signaling AKT-mediated inactivation of FOXO1A Signaling by Ligand-Responsive EGFR Variants in Cancer IRS-related events NGF signalling via TRKA from the plasma membrane Negative regulation of the PI3K/AKT network Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of TSC complex formation by PKB Signaling by FGFR IRS-mediated signalling TCF dependent signaling in response to WNT Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) GPVI-mediated activation cascade Signaling by WNT in cancer PKB-mediated events PI3K Cascade	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease PIP3 activates AKT signaling AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) HSF1-dependent transactivation PI3K/AKT activation PI-3K cascade PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signaling by PDGF DAP12 interactions Signalling by NGF GAB1 signalosome Signaling by Ligand-Responsive EGFR Variants in Cancer Cellular response to heat stress NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by FGFR Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System	N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
AKT2 and GSK3B	v-akt murine thymoma viral oncogene homolog 2	glycogen synthase kinase 3 beta	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Activation of BH3-only proteins mTOR signalling Signaling by Wnt Activation of PKB Signaling by EGFRvIII in Cancer AKT phosphorylates targets in the cytosol Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling Regulation of beta-cell development PI3K/AKT activation PI-3K cascade RNF mutants show enhanced WNT signaling and proliferation PDE3B signalling PKB-mediated events PI3K Cascade Signaling by PDGF Downregulation of ERBB2:ERBB3 signaling DAP12 interactions GAB1 signalosome misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling G-protein beta:gamma signalling CD28 co-stimulation CD28 dependent PI3K/Akt signaling PDE3B signalling Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by ERBB2 Activation of BAD and translocation to mitochondria Signaling by EGFR GPCR downstream signaling Signaling by VEGF AKT phosphorylates targets in the nucleus Downstream signal transduction Regulation of gene expression in beta cells Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Platelet activation, signaling and aggregation Adaptive Immune System Inhibition of TSC complex formation by PKB Activation of PKB Costimulation by the CD28 family IRS-mediated signalling PIP3 activates AKT signaling mTOR signalling Translocation of GLUT4 to the plasma membrane IGF1R signaling cascade deactivation of the beta-catenin transactivating complex VEGFA-VEGFR2 Pathway IRS-related events triggered by IGF1R G beta:gamma signalling through PI3Kgamma PI3K events in ERBB2 signaling VEGFR2 mediated vascular permeability Downstream signaling of activated FGFR Programmed Cell Death XAV939 inhibits tankyrase, stabilizing AXIN Intrinsic Pathway for Apoptosis Signaling by Insulin receptor Innate Immune System Signalling by NGF Insulin receptor signalling cascade CTLA4 inhibitory signaling AKT-mediated inactivation of FOXO1A Signaling by Ligand-Responsive EGFR Variants in Cancer IRS-related events NGF signalling via TRKA from the plasma membrane Negative regulation of the PI3K/AKT network Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of TSC complex formation by PKB Signaling by FGFR IRS-mediated signalling TCF dependent signaling in response to WNT Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) GPVI-mediated activation cascade Signaling by WNT in cancer PKB-mediated events PI3K Cascade	Signaling by the B Cell Receptor (BCR) Hedgehog 'off' state Signaling by FGFR in disease misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Degradation of beta-catenin by the destruction complex PI3K/AKT activation PI-3K cascade RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Signaling by PDGF DAP12 interactions GAB1 signalosome misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR deletions in the AMER1 gene destabilize the destruction complex AMER1 mutants destabilize the destruction complex Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer CRMPs in Sema3A signaling Adaptive Immune System Axon guidance PIP3 activates AKT signaling APC truncation mutants have impaired AXIN binding APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated PI3K events in ERBB2 signaling Downstream signaling of activated FGFR XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System Signalling by NGF Semaphorin interactions Signaling by Ligand-Responsive EGFR Variants in Cancer Regulation of HSF1-mediated heat shock response Cellular response to heat stress NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by FGFR TCF dependent signaling in response to WNT Signaling by Hedgehog deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer GLI3 is processed to GLI3R by the proteasome Degradation of GLI2 by the proteasome	N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	Lithium 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione I-5 N-(4-Methoxybenzyl)-N\'-(5-Nitro-1,3-Thiazol-2-Yl)Urea Staurosporine Indirubin-3\'-Monoxime Adenosine-5\'-Diphosphate (3e)-6\'-Bromo-2,3\'-Biindole-2\',3(1h,1\'h)-Dione 3-Oxime Alsterpaullone Phosphoaminophosphonic Acid-Adenylate Ester 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2\'H-2,3\'-biindol-2\'-one N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
AKT2 and HSP90AA1	v-akt murine thymoma viral oncogene homolog 2	heat shock protein 90kDa alpha (cytosolic), class A member 1	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Activation of BH3-only proteins mTOR signalling Signaling by Wnt Activation of PKB Signaling by EGFRvIII in Cancer AKT phosphorylates targets in the cytosol Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling Regulation of beta-cell development PI3K/AKT activation PI-3K cascade RNF mutants show enhanced WNT signaling and proliferation PDE3B signalling PKB-mediated events PI3K Cascade Signaling by PDGF Downregulation of ERBB2:ERBB3 signaling DAP12 interactions GAB1 signalosome misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling G-protein beta:gamma signalling CD28 co-stimulation CD28 dependent PI3K/Akt signaling PDE3B signalling Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by ERBB2 Activation of BAD and translocation to mitochondria Signaling by EGFR GPCR downstream signaling Signaling by VEGF AKT phosphorylates targets in the nucleus Downstream signal transduction Regulation of gene expression in beta cells Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Platelet activation, signaling and aggregation Adaptive Immune System Inhibition of TSC complex formation by PKB Activation of PKB Costimulation by the CD28 family IRS-mediated signalling PIP3 activates AKT signaling mTOR signalling Translocation of GLUT4 to the plasma membrane IGF1R signaling cascade deactivation of the beta-catenin transactivating complex VEGFA-VEGFR2 Pathway IRS-related events triggered by IGF1R G beta:gamma signalling through PI3Kgamma PI3K events in ERBB2 signaling VEGFR2 mediated vascular permeability Downstream signaling of activated FGFR Programmed Cell Death XAV939 inhibits tankyrase, stabilizing AXIN Intrinsic Pathway for Apoptosis Signaling by Insulin receptor Innate Immune System Signalling by NGF Insulin receptor signalling cascade CTLA4 inhibitory signaling AKT-mediated inactivation of FOXO1A Signaling by Ligand-Responsive EGFR Variants in Cancer IRS-related events NGF signalling via TRKA from the plasma membrane Negative regulation of the PI3K/AKT network Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of TSC complex formation by PKB Signaling by FGFR IRS-mediated signalling TCF dependent signaling in response to WNT Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) GPVI-mediated activation cascade Signaling by WNT in cancer PKB-mediated events PI3K Cascade	HSF1 activation Regulatory RNA pathways Signaling by EGFRvIII in Cancer Regulation of PLK1 Activity at G2/M Transition Influenza Life Cycle Influenza Viral RNA Transcription and Replication Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Uptake and actions of bacterial toxins EPH-Ephrin signaling Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation Fcgamma receptor (FCGR) dependent phagocytosis Recruitment of mitotic centrosome proteins and complexes Regulation of actin dynamics for phagocytic cup formation vRNP Assembly Influenza Infection Signaling by ERBB2 Signaling by VEGF Signaling by EGFR in Cancer Sema3A PAK dependent Axon repulsion Mitotic G2-G2/M phases Uptake and function of diphtheria toxin PIWI-interacting RNA (piRNA) biogenesis Organelle biogenesis and maintenance Axon guidance Attenuation phase G2/M Transition VEGFA-VEGFR2 Pathway HSF1-dependent transactivation EPHA-mediated growth cone collapse Metabolism of nitric oxide VEGFR2 mediated vascular permeability Loss of Nlp from mitotic centrosomes Scavenging by Class F Receptors eNOS activation and regulation Innate Immune System Semaphorin interactions Signaling by Ligand-Responsive EGFR Variants in Cancer Assembly of the primary cilium Cellular response to heat stress Anchoring of the basal body to the plasma membrane Cell Cycle, Mitotic eNOS activation Loss of proteins required for interphase microtubule organizationÂ from the centrosome Centrosome maturation Constitutive Signaling by EGFRvIII	N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	Rifabutin Nedocromil 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine Geldanamycin 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid 17-Dmag 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine Adenosine-5\'-Diphosphate 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol 4-[4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-3-METHYL-1H-PYRAZOL-5-YL]-6-ETHYLBENZENE-1,3-DIOL 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H- 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
AKT2 and CHUK	v-akt murine thymoma viral oncogene homolog 2	conserved helix-loop-helix ubiquitous kinase	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Activation of BH3-only proteins mTOR signalling Signaling by Wnt Activation of PKB Signaling by EGFRvIII in Cancer AKT phosphorylates targets in the cytosol Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling Regulation of beta-cell development PI3K/AKT activation PI-3K cascade RNF mutants show enhanced WNT signaling and proliferation PDE3B signalling PKB-mediated events PI3K Cascade Signaling by PDGF Downregulation of ERBB2:ERBB3 signaling DAP12 interactions GAB1 signalosome misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling G-protein beta:gamma signalling CD28 co-stimulation CD28 dependent PI3K/Akt signaling PDE3B signalling Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by ERBB2 Activation of BAD and translocation to mitochondria Signaling by EGFR GPCR downstream signaling Signaling by VEGF AKT phosphorylates targets in the nucleus Downstream signal transduction Regulation of gene expression in beta cells Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Platelet activation, signaling and aggregation Adaptive Immune System Inhibition of TSC complex formation by PKB Activation of PKB Costimulation by the CD28 family IRS-mediated signalling PIP3 activates AKT signaling mTOR signalling Translocation of GLUT4 to the plasma membrane IGF1R signaling cascade deactivation of the beta-catenin transactivating complex VEGFA-VEGFR2 Pathway IRS-related events triggered by IGF1R G beta:gamma signalling through PI3Kgamma PI3K events in ERBB2 signaling VEGFR2 mediated vascular permeability Downstream signaling of activated FGFR Programmed Cell Death XAV939 inhibits tankyrase, stabilizing AXIN Intrinsic Pathway for Apoptosis Signaling by Insulin receptor Innate Immune System Signalling by NGF Insulin receptor signalling cascade CTLA4 inhibitory signaling AKT-mediated inactivation of FOXO1A Signaling by Ligand-Responsive EGFR Variants in Cancer IRS-related events NGF signalling via TRKA from the plasma membrane Negative regulation of the PI3K/AKT network Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of TSC complex formation by PKB Signaling by FGFR IRS-mediated signalling TCF dependent signaling in response to WNT Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) GPVI-mediated activation cascade Signaling by WNT in cancer PKB-mediated events PI3K Cascade	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Signaling by EGFRvIII in Cancer AKT phosphorylates targets in the cytosol RIP-mediated NFkB activation via ZBP1 IRAK1 recruits IKK complex Signaling by SCF-KIT Toll Like Receptor TLR1:TLR2 Cascade DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) FCERI mediated NF-kB activation PI3K/AKT activation Toll Like Receptor 5 (TLR5) Cascade PI-3K cascade NOD1/2 Signaling Pathway MyD88 dependent cascade initiated on endosome Toll Like Receptor 9 (TLR9) Cascade IRAK1 recruits IKK complex Signaling by PDGF DAP12 interactions GAB1 signalosome TRIF-mediated TLR3/TLR4 signaling Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Toll Like Receptor 2 (TLR2) Cascade Signaling by ERBB2 Signaling by EGFR Signaling by Interleukins TCR signaling Downstream signal transduction Toll Like Receptor 3 (TLR3) Cascade Toll Like Receptor 4 (TLR4) Cascade Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling Interleukin-1 signaling PI3K/AKT Signaling in Cancer TAK1 activates NFkB by phosphorylation and activation of IKKs complex Adaptive Immune System Downstream TCR signaling PIP3 activates AKT signaling Toll Like Receptor 7/8 (TLR7/8) Cascade Toll Like Receptor TLR6:TLR2 Cascade Activated TLR4 signalling MyD88 cascade initiated on plasma membrane ZBP1(DAI) mediated induction of type I IFNs PI3K events in ERBB2 signaling Downstream signaling of activated FGFR TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation MyD88:Mal cascade initiated on plasma membrane Innate Immune System Signalling by NGF IKK complex recruitment mediated by RIP1 Cytosolic sensors of pathogen-associated DNA Cytokine Signaling in Immune system Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer MyD88-independent cascade Signaling by FGFR RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways Toll-Like Receptors Cascades Toll Like Receptor 10 (TLR10) Cascade Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways Activation of NF-kappaB in B cells TRAF6 mediated NF-kB activation NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation	N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
ALAS1 and CDKN1A	5-aminolevulinate synthase 1	cyclin-dependent kinase inhibitor 1A (p21, Cip1)	PPARA activates gene expression Heme biosynthesis Organelle biogenesis and maintenance Fatty acid, triacylglycerol, and ketone body metabolism Metabolism of lipids and lipoproteins Metabolism of porphyrins Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) Transcriptional activation of mitochondrial biogenesis Mitochondrial biogenesis	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Cellular Senescence p53-Dependent G1/S DNA damage checkpoint Cyclin E associated events during G1/S transition AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade G1/S Transition Removal of licensing factors from origins Switching of origins to a post-replicative state Mitotic G1-G1/S phases Signaling by PDGF DAP12 interactions DNA Damage/Telomere Stress Induced Senescence GAB1 signalosome Senescence-Associated Secretory Phenotype (SASP) S Phase Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR SCF(Skp2)-mediated degradation of p27/p21 Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Cyclin A:Cdk2-associated events at S phase entry SCF(Skp2)-mediated degradation of p27/p21 Adaptive Immune System PIP3 activates AKT signaling Orc1 removal from chromatin p53-Dependent G1 DNA Damage Response PI3K events in ERBB2 signaling Transcriptional activation of p53 responsive genes Downstream signaling of activated FGFR G1/S DNA Damage Checkpoints Innate Immune System Transcriptional activation of cell cycle inhibitor p21 Signalling by NGF Synthesis of DNA G1 Phase Regulation of DNA replication Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Cell Cycle, Mitotic Signaling by FGFR Orc1 removal from chromatin Cyclin D associated events in G1 Cell Cycle Checkpoints	Pyridoxal Phosphate Glycine
ALK and SHC1	anaplastic lymphoma receptor tyrosine kinase	SHC (Src homology 2 domain containing) transforming protein 1		Signaling by GPCR Signaling by EGFRvIII in Cancer Platelet Aggregation (Plug Formation) SHC1 events in ERBB2 signaling IRE1alpha activates chaperones Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Interleukin receptor SHC signaling SHC-mediated signalling G-protein beta:gamma signalling SHC-related events triggered by IGF1R Signaling by ERBB4 Signaling by ERBB2 Signaling by EGFR Signaling by Interleukins GPCR downstream signaling SHC1 events in ERBB4 signaling Signalling to RAS Signaling by EGFR in Cancer Interleukin-2 signaling Platelet activation, signaling and aggregation Interleukin-3, 5 and GM-CSF signaling Signalling to ERKs IGF1R signaling cascade XBP1(S) activates chaperone genes G beta:gamma signalling through PI3Kgamma Unfolded Protein Response (UPR) Signaling by Insulin receptor Signalling by NGF Insulin receptor signalling cascade SHC-mediated signalling Integrin alphaIIb beta3 signaling Signaling by Ligand-Responsive EGFR Variants in Cancer Cytokine Signaling in Immune system NGF signalling via TRKA from the plasma membrane SHC-related events Tie2 Signaling Signaling by Overexpressed Wild-Type EGFR in Cancer Cell surface interactions at the vascular wall SHC1 events in EGFR signaling Signal attenuation Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) Interleukin receptor SHC signaling GPVI-mediated activation cascade Constitutive Signaling by EGFRvIII SHC activation	Adenosine triphosphate
BIN1 and MYC	bridging integrator 1	v-myc avian myelocytomatosis viral oncogene homolog		Loss of Function of TGFBR2 in Cancer Signaling by NOTCH1 HD Domain Mutants in Cancer Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer SMAD2/3 MH2 Domain Mutants in Cancer Signaling by Wnt Cyclin E associated events during G1/S transition binding of TCF/LEF:CTNNB1 to target gene promoters TGFBR1 LBD Mutants in Cancer SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Generic Transcription Pathway RNF mutants show enhanced WNT signaling and proliferation G1/S Transition Signaling by NOTCH1 XAV939 inhibits tankyrase, stabilizing AXIN Signaling by NOTCH1 in Cancer Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants Mitotic G1-G1/S phases FBXW7 Mutants and NOTCH1 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Loss of Function of SMAD2/3 in Cancer Signaling by NOTCH formation of the beta-catenin:TCF transactivating complex TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer S Phase Cell Cycle, Mitotic Loss of Function of TGFBR1 in Cancer NOTCH1 Intracellular Domain Regulates Transcription Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex TCF dependent signaling in response to WNT Signaling by NOTCH1 PEST Domain Mutants in Cancer Cyclin A:Cdk2-associated events at S phase entry Signaling by WNT in cancer Constitutive Signaling by NOTCH1 PEST Domain Mutants SMAD4 MH2 Domain Mutants in Cancer
ANGPT2 and CDKN1A	angiopoietin 2	cyclin-dependent kinase inhibitor 1A (p21, Cip1)	Tie2 Signaling Cell surface interactions at the vascular wall	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Cellular Senescence p53-Dependent G1/S DNA damage checkpoint Cyclin E associated events during G1/S transition AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade G1/S Transition Removal of licensing factors from origins Switching of origins to a post-replicative state Mitotic G1-G1/S phases Signaling by PDGF DAP12 interactions DNA Damage/Telomere Stress Induced Senescence GAB1 signalosome Senescence-Associated Secretory Phenotype (SASP) S Phase Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR SCF(Skp2)-mediated degradation of p27/p21 Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Cyclin A:Cdk2-associated events at S phase entry SCF(Skp2)-mediated degradation of p27/p21 Adaptive Immune System PIP3 activates AKT signaling Orc1 removal from chromatin p53-Dependent G1 DNA Damage Response PI3K events in ERBB2 signaling Transcriptional activation of p53 responsive genes Downstream signaling of activated FGFR G1/S DNA Damage Checkpoints Innate Immune System Transcriptional activation of cell cycle inhibitor p21 Signalling by NGF Synthesis of DNA G1 Phase Regulation of DNA replication Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Cell Cycle, Mitotic Signaling by FGFR Orc1 removal from chromatin Cyclin D associated events in G1 Cell Cycle Checkpoints
APC and TPR	adenomatous polyposis coli	translocated promoter region, nuclear basket protein	misspliced GSK3beta mutants stabilize beta-catenin APC truncation mutants have impaired AXIN binding T41 mutants of beta-catenin aren't phosphorylated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Programmed Cell Death Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Apoptotic cleavage of cellular proteins misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Apoptotic execution phase phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Mitotic Prophase HIV Infection Nuclear import of Rev protein Regulatory RNA pathways Rev-mediated nuclear export of HIV RNA Nuclear Envelope Breakdown SLC-mediated transmembrane transport M Phase Influenza Life Cycle HIV Life Cycle Influenza Viral RNA Transcription and Replication Rev-mediated nuclear export of HIV RNA Myoclonic epilepsy of Lafora Glycogen storage diseases Transcriptional regulation by small RNAs Vpr-mediated nuclear import of PICs ISG15 antiviral mechanism Interferon Signaling Host Interactions of HIV factors Nuclear Pore Complex (NPC) Disassembly Regulation of Glucokinase by Glucokinase Regulatory Protein Cytokine Signaling in Immune system Interactions of Vpr with host cellular proteins Interactions of Rev with host cellular proteins Influenza Infection Hexose transport Cell Cycle, Mitotic Late Phase of HIV Life Cycle Antiviral mechanism by IFN-stimulated genes Viral Messenger RNA Synthesis Metabolism of carbohydrates Glucose transport
APC and PSMD1	adenomatous polyposis coli	proteasome (prosome, macropain) 26S subunit, non-ATPase, 1	misspliced GSK3beta mutants stabilize beta-catenin APC truncation mutants have impaired AXIN binding T41 mutants of beta-catenin aren't phosphorylated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Programmed Cell Death Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Apoptotic cleavage of cellular proteins misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Apoptotic execution phase phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Hedgehog 'off' state misspliced GSK3beta mutants stabilize beta-catenin Hh ligand biogenesis disease T41 mutants of beta-catenin aren't phosphorylated Downstream signaling events of B Cell Receptor (BCR) Degradation of beta-catenin by the destruction complex Stabilization of p53 S33 mutants of beta-catenin aren't phosphorylated AXIN mutants destabilize the destruction complex, activating WNT signaling Removal of licensing factors from origins Switching of origins to a post-replicative state Mitotic G1-G1/S phases Regulation of mRNA stability by proteins that bind AU-rich elements misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling DNA Replication Pre-Initiation S45 mutants of beta-catenin aren't phosphorylated APC/C:Cdc20 mediated degradation of mitotic proteins Regulation of APC/C activators between G1/S and early anaphase SCF(Skp2)-mediated degradation of p27/p21 deletions in the AMER1 gene destabilize the destruction complex Autodegradation of the E3 ubiquitin ligase COP1 AMER1 mutants destabilize the destruction complex Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint PCP/CE pathway Adaptive Immune System CDK-mediated phosphorylation and removal of Cdc6 Hedgehog ligand biogenesis APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Separation of Sister Chromatids HIV Infection Ubiquitin-dependent degradation of Cyclin D APC truncation mutants have impaired AXIN binding Assembly of the pre-replicative complex Autodegradation of Cdh1 by Cdh1:APC/C p53-Dependent G1 DNA Damage Response S37 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN p53-Independent DNA Damage Response p53-Independent G1/S DNA damage checkpoint G1/S DNA Damage Checkpoints Vpu mediated degradation of CD4 Synthesis of DNA M/G1 Transition Ubiquitin-dependent degradation of Cyclin D1 TCF dependent signaling in response to WNT SCF-beta-TrCP mediated degradation of Emi1 degradation of AXIN Signaling by Hedgehog Regulation of mitotic cell cycle Degradation of GLI1 by the proteasome degradation of DVL Cell Cycle Checkpoints Signaling by WNT in cancer GLI3 is processed to GLI3R by the proteasome Regulation of Apoptosis Degradation of GLI2 by the proteasome Signaling by the B Cell Receptor (BCR) Vif-mediated degradation of APOBEC3G Ubiquitin Mediated Degradation of Phosphorylated Cdc25A p53-Dependent G1/S DNA damage checkpoint truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Signaling by Wnt Cyclin E associated events during G1/S transition APC/C:Cdc20 mediated degradation of Securin AUF1 (hnRNP D0) destabilizes mRNA CDK-mediated phosphorylation and removal of Cdc6 RNF mutants show enhanced WNT signaling and proliferation G1/S Transition truncations of AMER1 destabilize the destruction complex Processing-defective Hh variants abrogate ligand secretion Host Interactions of HIV factors phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex Regulation of activated PAK-2p34 by proteasome mediated degradation AXIN missense mutants destabilize the destruction complex S Phase APC/C-mediated degradation of cell cycle proteins Cyclin A:Cdk2-associated events at S phase entry SCF(Skp2)-mediated degradation of p27/p21 Mitotic Metaphase and Anaphase Regulation of ornithine decarboxylase (ODC) Antigen processing: Ubiquitination & Proteasome degradation Orc1 removal from chromatin Mitotic Anaphase M Phase APC truncation mutants are not K63 polyubiquitinated Metabolism of amino acids and derivatives Hedgehog 'on' state Programmed Cell Death Class I MHC mediated antigen processing & presentation Regulation of DNA replication Cell Cycle, Mitotic beta-catenin independent WNT signaling Orc1 removal from chromatin Activation of NF-kappaB in B cells Asymmetric localization of PCP proteins deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Cross-presentation of soluble exogenous antigens (endosomes) Antigen processing-Cross presentation CDT1 association with the CDC6:ORC:origin complex ER-Phagosome pathway		Bortezomib
APC and HGS	adenomatous polyposis coli	hepatocyte growth factor-regulated tyrosine kinase substrate	misspliced GSK3beta mutants stabilize beta-catenin APC truncation mutants have impaired AXIN binding T41 mutants of beta-catenin aren't phosphorylated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Programmed Cell Death Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Apoptotic cleavage of cellular proteins misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Apoptotic execution phase phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Signaling by EGFR EGFR downregulation Endosomal Sorting Complex Required For Transport (ESCRT) Signaling by EGFR in Cancer Signaling by Ligand-Responsive EGFR Variants in Cancer Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by EGFRvIII in Cancer
APC and AXIN1	adenomatous polyposis coli	axin 1	misspliced GSK3beta mutants stabilize beta-catenin APC truncation mutants have impaired AXIN binding T41 mutants of beta-catenin aren't phosphorylated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Programmed Cell Death Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Apoptotic cleavage of cellular proteins misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Apoptotic execution phase phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	misspliced GSK3beta mutants stabilize beta-catenin APC truncation mutants have impaired AXIN binding T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated deletions in the AMER1 gene destabilize the destruction complex AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling degradation of AXIN Signaling by WNT in cancer
APC and C4A	adenomatous polyposis coli	complement component 4A (Rodgers blood group)	misspliced GSK3beta mutants stabilize beta-catenin APC truncation mutants have impaired AXIN binding T41 mutants of beta-catenin aren't phosphorylated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Programmed Cell Death Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Apoptotic cleavage of cellular proteins misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Apoptotic execution phase phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Regulation of Complement cascade Complement cascade Activation of C3 and C5 Initial triggering of complement Innate Immune System
APC and RANBP9	adenomatous polyposis coli	RAN binding protein 9	misspliced GSK3beta mutants stabilize beta-catenin APC truncation mutants have impaired AXIN binding T41 mutants of beta-catenin aren't phosphorylated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Programmed Cell Death Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Apoptotic cleavage of cellular proteins misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Apoptotic execution phase phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Axon guidance L1CAM interactions
APC and XPO1	adenomatous polyposis coli	exportin 1	misspliced GSK3beta mutants stabilize beta-catenin APC truncation mutants have impaired AXIN binding T41 mutants of beta-catenin aren't phosphorylated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Programmed Cell Death Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Apoptotic cleavage of cellular proteins misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Apoptotic execution phase phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Loss of Function of TGFBR2 in Cancer Downregulation of TGF-beta receptor signaling SMAD2/3 MH2 Domain Mutants in Cancer Signaling by Wnt TGF-beta receptor signaling activates SMADs Influenza Life Cycle Export of Viral Ribonucleoproteins from Nucleus RNF mutants show enhanced WNT signaling and proliferation Regulation of mRNA stability by proteins that bind AU-rich elements TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Host Interactions of HIV factors Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer Influenza Infection Late Phase of HIV Life Cycle Resolution of Sister Chromatid Cohesion Mitotic G2-G2/M phases Mitotic Metaphase and Anaphase Mitotic Prometaphase Separation of Sister Chromatids HIV Infection Rev-mediated nuclear export of HIV RNA G2/M Transition Mitotic Anaphase TGFBR1 LBD Mutants in Cancer HuR stabilizes mRNA deactivation of the beta-catenin transactivating complex M Phase HIV Life Cycle Rev-mediated nuclear export of HIV RNA Cyclin A/B1 associated events during G2/M transition XAV939 inhibits tankyrase, stabilizing AXIN NEP/NS2 Interacts with the Cellular Export Machinery Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer Interactions of Rev with host cellular proteins Cell Cycle, Mitotic Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex Signaling by TGF-beta Receptor Complex in Cancer TCF dependent signaling in response to WNT Signaling by WNT in cancer SMAD4 MH2 Domain Mutants in Cancer
APC and CREBBP	adenomatous polyposis coli	CREB binding protein	misspliced GSK3beta mutants stabilize beta-catenin APC truncation mutants have impaired AXIN binding T41 mutants of beta-catenin aren't phosphorylated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Programmed Cell Death Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Apoptotic cleavage of cellular proteins misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Apoptotic execution phase phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Signaling by NOTCH1 HD Domain Mutants in Cancer Metabolism of lipids and lipoproteins Signaling by Wnt Regulation of gene expression by Hypoxia-inducible Factor Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Generic Transcription Pathway Pre-NOTCH Transcription and Translation RNF mutants show enhanced WNT signaling and proliferation Signaling by NOTCH1 in Cancer Orphan transporters Chromatin organization misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Signaling by NOTCH formation of the beta-catenin:TCF transactivating complex Factors involved in megakaryocyte development and platelet production Chromatin modifying enzymes LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Signaling by NOTCH1 PEST Domain Mutants in Cancer Activation of gene expression by SREBF (SREBP) Transcriptional activation of mitochondrial biogenesis Constitutive Signaling by NOTCH1 PEST Domain Mutants PPARA activates gene expression Cellular response to hypoxia Organelle biogenesis and maintenance Regulation of Hypoxia-inducible Factor (HIF) by oxygen Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer Attenuation phase HATs acetylate histones RORA activates circadian gene expression Regulation of cholesterol biosynthesis by SREBP (SREBF) HSF1-dependent transactivation TRAF3-dependent IRF activation pathway Signaling by NOTCH1 Transcriptional regulation of white adipocyte differentiation XAV939 inhibits tankyrase, stabilizing AXIN Pre-NOTCH Expression and Processing Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants Innate Immune System FBXW7 Mutants and NOTCH1 in Cancer Fatty acid, triacylglycerol, and ketone body metabolism Cytosolic sensors of pathogen-associated DNA Cellular response to heat stress REV-ERBA represses gene expression Mitochondrial biogenesis Notch-HLH transcription pathway RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways NOTCH1 Intracellular Domain Regulates Transcription TCF dependent signaling in response to WNT TRAF6 mediated IRF7 activation YAP1- and WWTR1 (TAZ)-stimulated gene expression Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) Signaling by WNT in cancer BMAL1:CLOCK,NPAS2 activates circadian gene expression
APC and GSK3B	adenomatous polyposis coli	glycogen synthase kinase 3 beta	misspliced GSK3beta mutants stabilize beta-catenin APC truncation mutants have impaired AXIN binding T41 mutants of beta-catenin aren't phosphorylated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Programmed Cell Death Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Apoptotic cleavage of cellular proteins misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Apoptotic execution phase phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Signaling by the B Cell Receptor (BCR) Hedgehog 'off' state Signaling by FGFR in disease misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Degradation of beta-catenin by the destruction complex PI3K/AKT activation PI-3K cascade RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Signaling by PDGF DAP12 interactions GAB1 signalosome misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR deletions in the AMER1 gene destabilize the destruction complex AMER1 mutants destabilize the destruction complex Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer CRMPs in Sema3A signaling Adaptive Immune System Axon guidance PIP3 activates AKT signaling APC truncation mutants have impaired AXIN binding APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated PI3K events in ERBB2 signaling Downstream signaling of activated FGFR XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System Signalling by NGF Semaphorin interactions Signaling by Ligand-Responsive EGFR Variants in Cancer Regulation of HSF1-mediated heat shock response Cellular response to heat stress NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by FGFR TCF dependent signaling in response to WNT Signaling by Hedgehog deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer GLI3 is processed to GLI3R by the proteasome Degradation of GLI2 by the proteasome		Lithium 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione I-5 N-(4-Methoxybenzyl)-N\'-(5-Nitro-1,3-Thiazol-2-Yl)Urea Staurosporine Indirubin-3\'-Monoxime Adenosine-5\'-Diphosphate (3e)-6\'-Bromo-2,3\'-Biindole-2\',3(1h,1\'h)-Dione 3-Oxime Alsterpaullone Phosphoaminophosphonic Acid-Adenylate Ester 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2\'H-2,3\'-biindol-2\'-one N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE

Search Results for: Cancer